Monoclonal antibody therapies against SARS-CoV-2

D Focosi, S McConnell, A Casadevall… - The Lancet Infectious …, 2022‏ - thelancet.com
Monoclonal antibodies (mAbs) targeting the spike protein of SARS-CoV-2 have been widely
used in the ongoing COVID-19 pandemic. In this paper, we review the properties of mAbs …

Antibodies to combat viral infections: development strategies and progress

G Pantaleo, B Correia, C Fenwick, VS Joo… - Nature Reviews Drug …, 2022‏ - nature.com
Monoclonal antibodies (mAbs) are appealing as potential therapeutics and prophylactics for
viral infections owing to characteristics such as their high specificity and their ability to …

Persistent immune imprinting occurs after vaccination with the COVID-19 XBB. 1.5 mRNA booster in humans

MA Tortorici, A Addetia, AJ Seo, J Brown, K Sprouse… - Immunity, 2024‏ - cell.com
Immune imprinting describes how the first exposure to a virus shapes immunological
outcomes of subsequent exposures to antigenically related strains. Severe acute respiratory …

Intramuscular AZD7442 (tixagevimab–cilgavimab) for prevention of Covid-19

MJ Levin, A Ustianowski, S De Wit… - … England Journal of …, 2022‏ - Mass Medical Soc
Background The monoclonal-antibody combination AZD7442 is composed of tixagevimab
and cilgavimab, two neutralizing antibodies against severe acute respiratory syndrome …

Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies

Y Cao, J Wang, F Jian, T **ao, W Song, A Yisimayi… - Nature, 2022‏ - nature.com
Abstract The SARS-CoV-2 B. 1.1. 529 (Omicron) variant contains 15 mutations of the
receptor-binding domain (RBD). How Omicron evades RBD-targeted neutralizing antibodies …

mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant

WF Garcia-Beltran, KJS Denis, A Hoelzemer, EC Lam… - Cell, 2022‏ - cell.com
Recent surveillance has revealed the emergence of the SARS-CoV-2 Omicron variant (BA.
1/B. 1.1. 529) harboring up to 36 mutations in spike protein, the target of neutralizing …

Structural basis of SARS-CoV-2 Omicron immune evasion and receptor engagement

M McCallum, N Czudnochowski, LE Rosen, SK Zepeda… - Science, 2022‏ - science.org
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant of
concern evades antibody-mediated immunity that comes from vaccination or infection with …

Omicron variant (B. 1.1. 529): infectivity, vaccine breakthrough, and antibody resistance

J Chen, R Wang, NB Gilby, GW Wei - Journal of chemical …, 2022‏ - ACS Publications
The latest severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant Omicron
(B. 1.1. 529) has ushered panic responses around the world due to its contagious and …

Imprinted antibody responses against SARS-CoV-2 Omicron sublineages

YJ Park, D Pinto, AC Walls, Z Liu, A De Marco… - Science, 2022‏ - science.org
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron sublineages carry
distinct spike mutations resulting in escape from antibodies induced by previous infection or …

[HTML][HTML] Emerging variants of SARS-CoV-2 and novel therapeutics against coronavirus (COVID-19)

A Aleem, AS Ab, AK Slenker - 2021‏ - europepmc.org
Objectives: Describe the clinical manifestations, including extrapulmonary manifestations of
COVID-19. Outline the latest treatments available in the management of COVID-19 …